MX2024008910A - Farmaceutico para tratamiento de infeccion de nuevo coronavirus. - Google Patents
Farmaceutico para tratamiento de infeccion de nuevo coronavirus.Info
- Publication number
- MX2024008910A MX2024008910A MX2024008910A MX2024008910A MX2024008910A MX 2024008910 A MX2024008910 A MX 2024008910A MX 2024008910 A MX2024008910 A MX 2024008910A MX 2024008910 A MX2024008910 A MX 2024008910A MX 2024008910 A MX2024008910 A MX 2024008910A
- Authority
- MX
- Mexico
- Prior art keywords
- novel coronavirus
- pharmaceutical
- coronavirus infection
- pharmaceutical composition
- infection
- Prior art date
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title 1
- 241000711573 Coronaviridae Species 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022006725 | 2022-01-19 | ||
| JP2022012386 | 2022-01-28 | ||
| JP2022017132 | 2022-02-07 | ||
| JP2022027629 | 2022-02-25 | ||
| JP2022120325 | 2022-07-28 | ||
| JP2022149666 | 2022-09-21 | ||
| PCT/JP2023/001243 WO2023054732A2 (ja) | 2022-01-19 | 2023-01-18 | 新型コロナウイルス感染症治療用医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008910A true MX2024008910A (es) | 2024-07-25 |
Family
ID=85780780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008910A MX2024008910A (es) | 2022-01-19 | 2023-01-18 | Farmaceutico para tratamiento de infeccion de nuevo coronavirus. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250099474A1 (https=) |
| EP (1) | EP4467142A4 (https=) |
| JP (2) | JP7273455B1 (https=) |
| KR (1) | KR20240137021A (https=) |
| AU (1) | AU2023202177A1 (https=) |
| MX (1) | MX2024008910A (https=) |
| WO (1) | WO2023054732A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| LT4122926T (lt) | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| PL2399910T3 (pl) * | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| CN103153968B (zh) | 2010-08-10 | 2016-02-03 | 盐野义制药株式会社 | 三唑衍生物及含有其的具有镇痛作用的药物组合物 |
| JP6075621B2 (ja) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| TW201331188A (zh) | 2011-12-15 | 2013-08-01 | Shionogi & Co | 經取代之三□衍生物及含有其之醫藥組成物 |
| WO2013118855A1 (ja) | 2012-02-09 | 2013-08-15 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| WO2019087884A1 (ja) * | 2017-10-31 | 2019-05-09 | 富士フイルム株式会社 | 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー |
| EP4282420A4 (en) * | 2021-01-20 | 2024-11-27 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| EP4313097A4 (en) * | 2021-03-29 | 2025-03-19 | Shireen Nature Company for General Trading, Ltd. | Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions |
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| AU2022353486A1 (en) * | 2021-09-28 | 2024-05-02 | National University Corporation Hokkaido University | Pharmaceutical composition containing triazine derivative |
| EP4289432A4 (en) * | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
-
2023
- 2023-01-18 WO PCT/JP2023/001243 patent/WO2023054732A2/ja not_active Ceased
- 2023-01-18 US US18/729,630 patent/US20250099474A1/en active Pending
- 2023-01-18 AU AU2023202177A patent/AU2023202177A1/en active Pending
- 2023-01-18 MX MX2024008910A patent/MX2024008910A/es unknown
- 2023-01-18 KR KR1020247027109A patent/KR20240137021A/ko active Pending
- 2023-01-18 EP EP23714052.0A patent/EP4467142A4/en active Pending
- 2023-01-18 JP JP2023511553A patent/JP7273455B1/ja active Active
- 2023-04-26 JP JP2023072576A patent/JP2023105826A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7273455B1 (ja) | 2023-05-15 |
| WO2023054732A3 (ja) | 2023-06-15 |
| KR20240137021A (ko) | 2024-09-19 |
| TW202339757A (zh) | 2023-10-16 |
| US20250099474A1 (en) | 2025-03-27 |
| EP4467142A2 (en) | 2024-11-27 |
| JPWO2023054732A1 (https=) | 2023-04-06 |
| JP2023105826A (ja) | 2023-07-31 |
| AU2023202177A1 (en) | 2024-07-18 |
| WO2023054732A2 (ja) | 2023-04-06 |
| EP4467142A4 (en) | 2025-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008910A (es) | Farmaceutico para tratamiento de infeccion de nuevo coronavirus. | |
| MX2023014307A (es) | Inhibidores de proteasa como antivirales. | |
| MX2024003960A (es) | Compuestos antivirales que contienen nitrilo. | |
| ZA202310378B (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof | |
| ZA202402178B (en) | 3clpro protease inhibitor | |
| GEAP202416135A (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| MX2023009052A (es) | Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo. | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MX2025001749A (es) | Compuesto como inhibidor del canal de sodio dependiente del voltaje | |
| MX2025006915A (es) | Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta | |
| MX2026001155A (es) | Derivado de amida sustituido con heterociclilalquinilo, metodo de preparacion del mismo y uso del mismo | |
| MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
| PH12022552110A1 (en) | Quinolyl phosphine oxide compound, and composition and application thereof | |
| MX2024010480A (es) | Uso de inhibidor de captacion triple para el tratamiento de la depresion atipica. | |
| MX2024009608A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2025009982A (es) | Sal de antagonista derivado que contiene anillo aromatico, metodo de preparacion del mismo y aplicacion del mismo | |
| MX2024015733A (es) | Compuestos para el tratamiento de una infeccion por coronavirus | |
| MX2025004094A (es) | Inhibidores y/o degradadores de hsd17b13 | |
| PH12023553004A1 (en) | Modulators of trex1 | |
| MX2023014704A (es) | Inhibidores de proteasa para el tratamiento de infecciones por coronavirus. | |
| WO2022118016A3 (en) | Enzyme inhibitors | |
| CA3242795A1 (en) | Pharmaceutical for treatment of novel coronavirus infection | |
| WO2022129210A3 (en) | Inhibition of virus protease | |
| CA3242747A1 (en) | Plpro inhibitors | |
| MX2023012678A (es) | Moduladores de exonucleasa 1 de tres reparaciones principales (trex1). |